Innovating(IN) Shorter(S), All- Oral, Precised(P), Individualized(I) Treatment Regimen(RE) for Rifampicin Resistant Tuberculosis(INSPIRE-TB)
Condition(s):Multidrug Resistant TuberculosisLast Updated:March 22, 2023Recruiting
Hide Studies Not Open or Pending
Condition(s):Multidrug Resistant TuberculosisLast Updated:March 22, 2023Recruiting
Condition(s):Tuberculosis, Multidrug-ResistantLast Updated:October 25, 2017Completed
Condition(s):Multidrug Resistant OrganismsLast Updated:July 21, 2017Unknown status
Condition(s):HIV-1-infectionLast Updated:March 5, 2024Completed
Condition(s):Multidrug Resistant TuberculosisLast Updated:April 6, 2023Active, not recruiting
Condition(s):Blood DisordersLast Updated:June 4, 2015Unknown status
Condition(s):Multidrug Resistant Bacterial InfectionLast Updated:February 22, 2024Recruiting
Condition(s):Pneumonia; Critical IllnessLast Updated:August 1, 2017Completed
Condition(s):Pre-Extensively Drug-Resistant Pulmonary TB; Treatment Intolerant Multidrug-Resistant Pulmonary TB; Non-responsive Multidrug-Resistant Pulmonary TBLast Updated:January 3, 2024Active, not recruiting
Condition(s):Infections; Critical Illness; Superinfection; Organ Failure, Multiple; Ventilator Associated Pneumonia; Septic ShockLast Updated:August 2, 2023Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.